BR112018008838A8 - método para tratar, prevenir, melhorar ou administrar uma doença epiléptica - Google Patents
método para tratar, prevenir, melhorar ou administrar uma doença epilépticaInfo
- Publication number
- BR112018008838A8 BR112018008838A8 BR112018008838A BR112018008838A BR112018008838A8 BR 112018008838 A8 BR112018008838 A8 BR 112018008838A8 BR 112018008838 A BR112018008838 A BR 112018008838A BR 112018008838 A BR112018008838 A BR 112018008838A BR 112018008838 A8 BR112018008838 A8 BR 112018008838A8
- Authority
- BR
- Brazil
- Prior art keywords
- ameliorating
- treating
- preventing
- administering
- epileptic disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248891P | 2015-10-30 | 2015-10-30 | |
US62/248,891 | 2015-10-30 | ||
PCT/US2016/059262 WO2017075312A1 (en) | 2015-10-30 | 2016-10-28 | Methods for treating epilepsy |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018008838A2 BR112018008838A2 (pt) | 2018-11-06 |
BR112018008838A8 true BR112018008838A8 (pt) | 2019-02-26 |
Family
ID=58632013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008838A BR112018008838A8 (pt) | 2015-10-30 | 2016-10-28 | método para tratar, prevenir, melhorar ou administrar uma doença epiléptica |
Country Status (15)
Country | Link |
---|---|
US (2) | US10517853B2 (zh) |
EP (1) | EP3368042A4 (zh) |
JP (1) | JP2018531975A (zh) |
KR (1) | KR20180081516A (zh) |
CN (1) | CN108348527A (zh) |
AR (1) | AR106530A1 (zh) |
BR (1) | BR112018008838A8 (zh) |
CA (1) | CA3003132A1 (zh) |
CO (1) | CO2018004684A2 (zh) |
HK (1) | HK1251965A1 (zh) |
IL (1) | IL258988A (zh) |
MX (1) | MX2018005361A (zh) |
PH (1) | PH12018500885A1 (zh) |
TW (1) | TW201729807A (zh) |
WO (1) | WO2017075312A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220105174A (ko) | 2015-10-09 | 2022-07-26 | 유니버시티 오브 사우스앰톤 | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 |
CN109312343B (zh) | 2015-12-14 | 2022-09-27 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
RS65031B1 (sr) | 2017-08-25 | 2024-02-29 | Stoke Therapeutics Inc | Antisens oligomeri za lečenje stanja i bolesti |
US11301527B2 (en) | 2019-05-06 | 2022-04-12 | Acto Technologies Inc. | Event-driven content recommendation engine |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
CA3170273A1 (en) * | 2020-03-17 | 2021-09-23 | Sumitomo Pharma Co., Ltd. | Oxadiazole derivative |
WO2021231107A1 (en) | 2020-05-11 | 2021-11-18 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
CN117987538A (zh) * | 2024-04-07 | 2024-05-07 | 北京诺禾致源科技股份有限公司 | 用于检测depdc5突变基因的试剂在制备诊断或预测家族性局灶性癫痫伴可变灶1型的试剂盒中的应用 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL291628A (zh) | 1962-04-17 | |||
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
US6071700A (en) | 1995-01-20 | 2000-06-06 | University Of Massachusetts | Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions |
SK30198A3 (en) | 1995-09-07 | 1998-08-05 | Novartis Ag | Substituted phosphinic compounds and their use as pharmaceuticals |
CN1216534A (zh) | 1996-04-26 | 1999-05-12 | 日本曹达株式会社 | 杂环取代的新颖苯衍生物和除草剂 |
DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
AU712057B2 (en) | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
ES2329739T3 (es) | 1997-04-07 | 2009-11-30 | Georgetown University | Analogos de cocaina. |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
AU9647998A (en) | 1997-10-27 | 1999-05-17 | Nippon Soda Co., Ltd. | Novel benzoylpyrazole derivatives and herbicides |
IL139187A0 (en) | 1998-04-23 | 2001-11-25 | Cortech Inc | Cysteine protease inhibitors |
ID28385A (id) | 1998-10-08 | 2001-05-17 | Smithkline Beecham Plc | Turunan-turunan tetrahidrobenzazepina yang berguna sebagai modulator reseptor d3 dopamina (bahan antipsikotik) |
ATE259803T1 (de) | 1998-10-09 | 2004-03-15 | Janssen Pharmaceutica Nv | 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung |
AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
CZ20012277A3 (cs) | 1998-12-23 | 2001-11-14 | Smithkline Beecham Corporation | Inhibitory proteázy |
WO2000058280A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives de sulfonamide carbocyclique |
WO2000058304A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives sulfonamides heterocycliques |
AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
CN1356977A (zh) | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | 胰高血糖素拮抗剂/反向激动剂 |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP2003528106A (ja) | 2000-03-22 | 2003-09-24 | メルク フロスト カナダ アンド カンパニー | Ptp−1b阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類 |
WO2001083464A1 (fr) | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire |
GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
CA2409827C (en) | 2000-05-22 | 2010-06-01 | Aventis Pharmaceuticals Products Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
CA2342432A1 (en) | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Novel compound |
GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
BR0209054A (pt) | 2001-04-19 | 2004-04-20 | Bayer Ag | Arilsulfonamidas como agentes antivirais |
KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
AR041508A1 (es) | 2002-08-09 | 2005-05-18 | Astra Ab | Compuestos con actividad en los receptores de glutamato metabotropicos |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
AU2003901425A0 (en) * | 2003-03-27 | 2003-04-10 | Bionomics Limited | A diagnostic method for epilepsy |
KR100729883B1 (ko) | 2003-03-28 | 2007-06-18 | 화이자 프로덕츠 인코포레이티드 | 죽상경화증 및 비만증을 치료하기 위한 cetp억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체 |
ZA200508298B (en) | 2003-04-11 | 2007-01-31 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds |
US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
EP1799659A1 (en) | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
US8716321B2 (en) | 2005-04-08 | 2014-05-06 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole |
CN101193632A (zh) * | 2005-04-08 | 2008-06-04 | Ptc医疗公司 | 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物 |
WO2006133508A1 (en) * | 2005-06-16 | 2006-12-21 | Bionomics Limited | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
MX2008012515A (es) | 2006-03-30 | 2008-11-19 | Ptc Therapeutics Inc | Metodos para la produccion de proteina funcional a partir de adn que tiene una mutacion sin sentido y el tratamiento de trastornos asociados con la misma. |
WO2007123848A2 (en) | 2006-04-19 | 2007-11-01 | Brown University | Therapeutic compositions containing modified class i slrp proteins |
NZ598012A (en) | 2006-09-08 | 2013-08-30 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
CL2007002743A1 (es) | 2006-09-25 | 2008-07-11 | Pct Therapeutics Inc Soc Organ | Forma cristalina del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico; composicion farmaceutica que comprende a dicha forma cristalina; y su uso para modular la terminacion prematura de traslado o decaimiento de marn, tales como carcicoma. |
WO2008130370A1 (en) | 2006-09-25 | 2008-10-30 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
SI2073805T1 (sl) | 2006-10-12 | 2015-10-30 | Ptc Therapeutics, Inc. | Postopki za odmerjanje peroralno aktivnega 1,2,4-oksadiazola za zdravljenje supresije nesmiselnih mutacij |
WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
CA2696863C (en) | 2007-10-04 | 2016-10-18 | Anna Quattropani | Oxadiazole derivatives |
AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
ES2594302T3 (es) | 2007-12-17 | 2016-12-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético |
CN102076670B (zh) | 2008-06-24 | 2013-05-22 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
PL2344129T3 (pl) | 2008-10-07 | 2018-07-31 | Horizon Orphan Llc | Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych |
RU2398770C1 (ru) | 2009-03-27 | 2010-09-10 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота |
EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
US20120289476A1 (en) | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
PL2600865T3 (pl) * | 2010-08-05 | 2019-05-31 | Institut National De La Sante Et De La Rech Medicale | Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek |
TWI695717B (zh) | 2014-03-06 | 2020-06-11 | 美商 Ptc 治療公司 | 1,2,4-二唑苯甲酸之鹽及醫藥組合物 |
US20170196842A1 (en) | 2014-06-06 | 2017-07-13 | Ptc Therapeutics, Inc. | Methods of treatment using a 1,2,4-oxadiazole benzoic acid |
-
2016
- 2016-10-28 JP JP2018522022A patent/JP2018531975A/ja active Pending
- 2016-10-28 CN CN201680063273.8A patent/CN108348527A/zh active Pending
- 2016-10-28 US US15/771,379 patent/US10517853B2/en active Active
- 2016-10-28 MX MX2018005361A patent/MX2018005361A/es unknown
- 2016-10-28 CA CA3003132A patent/CA3003132A1/en not_active Abandoned
- 2016-10-28 BR BR112018008838A patent/BR112018008838A8/pt not_active Application Discontinuation
- 2016-10-28 WO PCT/US2016/059262 patent/WO2017075312A1/en active Application Filing
- 2016-10-28 AR ARP160103314A patent/AR106530A1/es unknown
- 2016-10-28 TW TW105135155A patent/TW201729807A/zh unknown
- 2016-10-28 EP EP16860855.2A patent/EP3368042A4/en not_active Withdrawn
- 2016-10-28 KR KR1020187013165A patent/KR20180081516A/ko unknown
-
2018
- 2018-04-25 PH PH12018500885A patent/PH12018500885A1/en unknown
- 2018-04-26 IL IL258988A patent/IL258988A/en unknown
- 2018-04-30 CO CONC2018/0004684A patent/CO2018004684A2/es unknown
- 2018-08-31 HK HK18111236.1A patent/HK1251965A1/zh unknown
-
2019
- 2019-11-07 US US16/676,806 patent/US20200188362A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO2018004684A2 (es) | 2018-08-10 |
TW201729807A (zh) | 2017-09-01 |
MX2018005361A (es) | 2018-06-07 |
HK1251965A1 (zh) | 2019-05-10 |
IL258988A (en) | 2018-06-28 |
KR20180081516A (ko) | 2018-07-16 |
WO2017075312A1 (en) | 2017-05-04 |
AR106530A1 (es) | 2018-01-24 |
CA3003132A1 (en) | 2017-05-04 |
US20200188362A1 (en) | 2020-06-18 |
JP2018531975A (ja) | 2018-11-01 |
CN108348527A (zh) | 2018-07-31 |
US20180333397A1 (en) | 2018-11-22 |
EP3368042A1 (en) | 2018-09-05 |
EP3368042A4 (en) | 2019-06-26 |
BR112018008838A2 (pt) | 2018-11-06 |
US10517853B2 (en) | 2019-12-31 |
PH12018500885A1 (en) | 2018-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008838A8 (pt) | método para tratar, prevenir, melhorar ou administrar uma doença epiléptica | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
AR087918A1 (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf | |
MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
EA201890811A1 (ru) | Способы лечения мышечной дистрофии | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112016007487A2 (pt) | composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica | |
BR112022007721A2 (pt) | Método para o tratamento da demência | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
EA201592265A1 (ru) | Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения | |
BR112013010345A2 (pt) | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção | |
MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
AR097179A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina | |
RU2014142752A (ru) | Способы воздействия на экспрессию гена лактазы | |
BR112016018145A2 (pt) | micrornas e composições compreendendo os mesmos para tratamento e diagnóstico de condições médicas associadas à serotonina, adrenalina, noradrenalina, glutamato e corticotropina que liberam hormônio | |
RU2014148258A (ru) | Способы воздействия на экспрессию гена ADA | |
RU2014144700A (ru) | Способы воздействия на экспрессию гена UBE3А |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |